Deutsche Bank’s Marker Therapeutics MRKR Stock Holding History

Deutsche Bank’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,997	Closed	-$45K	–	4717
2021 Q1	$45K	Sell	1,997 -185	-8%	-$4.23K	﹤0.01%	4261
2020 Q4	$31K	Buy	2,182 +275	+14%	+$4.27K	﹤0.01%	4197
2020 Q3	$29K	Buy	1,907 +262	+16%	+$4.78K	﹤0.01%	4055
2020 Q2	$34K	Sell	1,645 -1,246	-43%	-$27.2K	﹤0.01%	3959
2020 Q1	$55K	Sell	2,891 -953	-25%	-$24.3K	﹤0.01%	3501
2019 Q4	$109K	Buy	3,844 +3,045	+381%	+$111K	﹤0.01%	3547
2019 Q3	$39K	Sell	799 -1,368	-63%	-$80.8K	﹤0.01%	4061
2019 Q2	$170K	Buy	+2,167	New	+$129K	﹤0.01%	3919
2018 Q1	–	Hold	0	–	–	–	5518
2017 Q4	–	Hold	0	–	–	–	5074
2017 Q3	–	Hold	0	–	–	–	5001
2017 Q2	–	Hold	0	–	–	–	5048
2017 Q1	–	Hold	0	–	–	–	5037
2016 Q4	–	Hold	0	–	–	–	5014

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank's MRKR Position: Q2 2021 in Review

Deutsche Bank sold out of Marker Therapeutics (MRKR) in Q2 2021, closing a stake of 1,997 shares — an estimated $45K sold.

Deutsche Bank first reported a position in MRKR in Q2 2019 and held it in 8 quarters. The position peaked at $170K in Q2 2019. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

Deutsche Bank reported no remaining Marker Therapeutics position as of Q2 2021 after selling out during the quarter.
Deutsche Bank sold 1,997 Marker Therapeutics shares in Q2 2021, an estimated $45K.
Deutsche Bank first reported a position in Marker Therapeutics in Q2 2019 and held it in 8 quarters.
Deutsche Bank's Marker Therapeutics position peaked at $170K in Q2 2019.
74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on Deutsche Bank's 13F filing for Q2 2021, filed 11 Aug 2021.